.Attributes Medication, Published online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) procedure of people along with HER2+ innovative breast cancer and also energetic or steady brain metastases presented constant intracranial activity as well as wide spread efficiency of T-DXd.